UPDATE: Xenon Genetics Snaps Up QuantaNova s Lipid Genomics Technology | GenomeWeb

NEW YORK, Oct. 24 - Xenon Genetics, a privately held Canadian genomics firm, has acquired the lipid metabolism drug-discovery program of QuantaNova Canada, Xenon said on Wednesday. 

The acquisition, which includes a portfolio of novel genes and proprietary screening and diagnostic assays, is intended to help Xenon develop therapeutics for diabetes, obesity, and cardiovascular disease, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.